TD Cowen reinstates coverage on Tempus AI with 'buy' after Ambry deal
TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...
Tempus AI shares rise 5% pre-market on continued momentum, Ambry Genetics acquisition
Shares of Tempus AI , Inc. (NASDAQ:TEM) climbed 5% in pre-open trading Tuesday following the completion of its acquisition of ...
Tempus AI (TEM) Acquires Ambry Genetics in $600M Precision Medicine Push
We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at where Tempus AI, Inc.
Nature6y
Breaking new ground through high-quality genetic testing
Ambry Genetics drives innovation in diagnostics by launching cutting-edge genetic tests and technologies. Its broad collaborations, novel research projects, and networks for data sharing ...
The Scientist11y
Another Lawsuit over Genetic Tests
Myriad and its partners in the suit says that even though the patents on the natural genes are invalidated, Gene by Gene and Ambry Genetics are still in violation of 10 patents on the BRCA gene ...
The Scientist6y
Study Finds Inaccuracies in 40 Percent of DTC Genetic Testing Results
“Such a high rate of a false positives in this particular study was unexpected,” says study coauthor Stephany Tandy-Connor of Ambry Genetics, in a statement. She notes that differences in testing ...